DK0843731T3 - Adenovirusvektorer til genterapi - Google Patents

Adenovirusvektorer til genterapi

Info

Publication number
DK0843731T3
DK0843731T3 DK96909800T DK96909800T DK0843731T3 DK 0843731 T3 DK0843731 T3 DK 0843731T3 DK 96909800 T DK96909800 T DK 96909800T DK 96909800 T DK96909800 T DK 96909800T DK 0843731 T3 DK0843731 T3 DK 0843731T3
Authority
DK
Denmark
Prior art keywords
gene therapy
vectors
adenovirus vectors
adenovirus
novel
Prior art date
Application number
DK96909800T
Other languages
English (en)
Inventor
Samuel C Wadsworth
Donna Armentano
Helen Romanczuk
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/409,874 external-priority patent/US5707618A/en
Application filed by Genzyme Corp filed Critical Genzyme Corp
Application granted granted Critical
Publication of DK0843731T3 publication Critical patent/DK0843731T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4712—Cystic fibrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
DK96909800T 1995-03-24 1996-03-20 Adenovirusvektorer til genterapi DK0843731T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/409,874 US5707618A (en) 1995-03-24 1995-03-24 Adenovirus vectors for gene therapy
US08/540,077 US5824544A (en) 1995-03-24 1995-10-06 Adenovirus vectors for gene therapy
PCT/US1996/003818 WO1996030534A1 (en) 1995-03-24 1996-03-20 Adenovirus vectors for gene therapy

Publications (1)

Publication Number Publication Date
DK0843731T3 true DK0843731T3 (da) 2008-06-09

Family

ID=27020791

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96909800T DK0843731T3 (da) 1995-03-24 1996-03-20 Adenovirusvektorer til genterapi

Country Status (8)

Country Link
EP (1) EP0843731B1 (da)
JP (1) JP3827163B2 (da)
AT (1) ATE386130T1 (da)
AU (1) AU718772B2 (da)
CA (1) CA2226833C (da)
DK (1) DK0843731T3 (da)
ES (1) ES2300105T3 (da)
WO (1) WO1996030534A1 (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020191A (en) * 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
US5981275A (en) * 1997-04-14 1999-11-09 Genzyme Corporation Transgene expression system for increased persistence
US6100086A (en) 1997-04-14 2000-08-08 Genzyme Corporation Transgene expression systems
FR2774699B1 (fr) * 1997-11-17 2003-10-03 Rhone Poulenc Rorer Sa Methode de reduction des evenements de recombinaison homologue
WO1999057296A1 (en) * 1998-05-01 1999-11-11 Genzyme Corporation Partially deleted adenoviral vectors
CA2721011A1 (en) 1999-10-22 2001-05-03 Aventis Pasteur Limited Modified gp100 and uses thereof
CA2408328C (en) 2000-05-10 2012-04-17 Aventis Pasteur Limited Immunogenic polypeptides encoded by mage minigenes and uses thereof
JP4744771B2 (ja) * 2000-05-26 2011-08-10 大日本住友製薬株式会社 副作用を軽減した新規な組換えアデノウイルスベクター
DE10045687B4 (de) * 2000-09-15 2006-07-06 MICROMUN Privates Institut für Mikrobiologische Forschung GmbH Biotechnikum Greifswald Expressionskassetten und Adenovirusvektoren
US20030026783A1 (en) 2001-08-03 2003-02-06 Amine Abina Method of modulating neutralizing antibodies formation in mammals, and uses thereof in gene therapy, animal transgenesis and in functional inactivation of an endogenous proteins
CN1655827B (zh) 2002-05-27 2010-06-23 佩尔·松内·霍尔姆 腺病毒和编码其的核酸的新应用
US20070110719A1 (en) 2003-11-14 2007-05-17 Holm Per S Novel use of adenoviruses and nucleic acids that code for said viruses
US20090232800A1 (en) * 2004-12-31 2009-09-17 Per Sonne Holm E1-minus adenoviruses and use thereof
CA2592699C (en) * 2004-12-31 2023-02-21 Per Sonne Holm Method for reversing multiple resistance in animal cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU680459B2 (en) 1992-12-03 1997-07-31 Genzyme Corporation Gene therapy for cystic fibrosis
DK0797676T3 (da) * 1993-10-25 2006-04-18 Canji Inc Rekombinant adenoviral vektor og fremgangsmåder til anvendelse deraf
DE10234697A1 (de) 2002-07-30 2004-02-19 Morphochem Aktiengesellschaft für kombinatorische Chemie Neue Verbindungen zur Stimulation des Nervenwachstums, zur Inhibition der Narbengewebsbildung und/oder Reduktion eines Sekundärschadens

Also Published As

Publication number Publication date
ES2300105T3 (es) 2008-06-01
EP0843731A1 (en) 1998-05-27
ATE386130T1 (de) 2008-03-15
EP0843731B1 (en) 2008-02-13
WO1996030534A1 (en) 1996-10-03
JPH11506311A (ja) 1999-06-08
AU5318496A (en) 1996-10-16
JP3827163B2 (ja) 2006-09-27
AU718772B2 (en) 2000-04-20
CA2226833A1 (en) 1996-10-03
CA2226833C (en) 2009-12-15

Similar Documents

Publication Publication Date Title
EP1923467A3 (en) Adenovirus vectors for gene therapy
DK0843731T3 (da) Adenovirusvektorer til genterapi
WO1995006743A3 (en) Methods and compositions for the large scale production of recombinant adeno-associated virus
ATE312190T1 (de) Nukleinsaeure enthaltende zusammensetzungen, herstellung und verwendung
HUP0003331A2 (hu) Eljárás a C-szerocsoportba nem besorolható adenovirális vektorok előállítására
CY1106513T1 (el) Λεντινοϊικο τριπλο dna και οχηματα και ανασυνδυασμενα κυτταρα που περιεχουν λεντινοϊικο τριπλο dna
ATE466931T1 (de) Verbesserte adenovirusvektoren
FR2716682B1 (fr) Procédé de préparation de virus adéno-associés (AAV) recombinants et utilisations.
DK0584266T3 (da) Rekombinant virus udtrykkende carcinoembryonalt antigen og fremgangsmåder til anvendelse heraf
AU2790292A (en) Viral recombinant vectors for expression in muscle cells
ATE309378T1 (de) Abgeschwächter salmonellenstamm, gebraucht als vehikel zur oralen immunisierung
EP1017797A4 (en) NON-ORIGINATING PRIMATE LENTIVIRUS VECTORS AND PACKAGING SYSTEMS
DK1681355T3 (da) Sekvensspecifik DNA-rekombination i eukaryote celler
ATE432085T1 (de) Stimulationsfaktor für dendriten
AUPN477695A0 (en) Gene therapy
DK0632129T3 (da) Rekombinante foamy-virusvektorer til medicinsk og diagnostisk anvendelse, og fremgangsmåder til at præparere rekombinante foamy-virusvektorer
CA2306449A1 (en) Rapid generation of stable mammalian cell lines producing high levels of recombinant proteins
EP1012603A4 (en) FUNCTIONAL FRAGMENTS OF THE HIV-1 VPR PROTEIN AND METHODS OF USE
WO1998037185A3 (en) Vectors for controlled gene expression
NZ505834A (en) Compositions containing polypeptides isolated from mycobacterium vaccae and methods for their use
EP1070122A4 (en) INDUCTION OF THE EXPRESSION OF APOPTOTIC OR CYTOTOXIC GENES BY CO-SUPPORT OF ADENOVIRAL MEDIATED GENES
MX9806041A (es) Proteina purificada sr-p70.
DK0781344T3 (da) Hidtil ukendt implantat og hidtil ukendt vektor til behandling af erhvervede sygdomme
NZ324157A (en) Conditionally replicating viral vectors and their use in treating HIV
WO2000004918A3 (de) Mittel zur immuntherapie von tumorerkrankungen